News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,858 Results
Type
Article (40017)
Company Profile (250)
Press Release (664590)
Multimedia
Podcasts (59)
Webinars (14)
Section
Business (204276)
Career Advice (2011)
Deals (35456)
Drug Delivery (95)
Drug Development (81145)
Employer Resources (172)
FDA (16249)
Job Trends (14887)
News (345511)
Policy (32610)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49571)
ALS (108)
Alzheimer's disease (1441)
Antibody-drug conjugate (ADC) (151)
Approvals (16245)
Artificial intelligence (308)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (365)
Cancer (2858)
Cardiovascular disease (212)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (497)
Cervical cancer (22)
Clinical research (66853)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2625)
CRISPR (56)
C-suite (324)
Cystic fibrosis (112)
Data (2991)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (137)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87450)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113739)
Executive appointments (845)
FDA (17894)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (928)
Gene editing (129)
Generative AI (22)
Gene therapy (372)
GLP-1 (780)
Government (4501)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2797)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16594)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (383)
MASH (90)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19577)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2116)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (427)
Opinion (217)
Ovarian cancer (101)
Pain (105)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (296)
Patient recruitment (163)
Peanut (50)
People (57682)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20828)
Phase II (29448)
Phase III (21917)
Pipeline (1626)
Policy (199)
Postmarket research (2563)
Preclinical (8870)
Press Release (64)
Prostate cancer (140)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (457)
Real estate (5917)
Recruiting (66)
Regulatory (22629)
Reports (50)
Research institute (2327)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (37)
Vaccines (778)
Venture capital (53)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (66)
Last 7 days (361)
Last 30 days (1884)
Last 365 days (31204)
2025 (16732)
2024 (35219)
2023 (40076)
2022 (51177)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35023)
2017 (32114)
2016 (31483)
2015 (37553)
2014 (31318)
2013 (26346)
2012 (28571)
2011 (29266)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38223)
Australia (6232)
California (7430)
Canada (2357)
China (669)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82100)
Florida (1116)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1020)
Massachusetts (5518)
Michigan (246)
Minnesota (449)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2070)
New Mexico (28)
New York (2082)
North Carolina (1079)
North Dakota (8)
Northern California (3272)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1610)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2778)
Tennessee (126)
Texas (1122)
United States (27523)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (631)
West Virginia (4)
Wisconsin (66)
704,858 Results for "ascletis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
July 15, 2025
·
3 min read
Press Releases
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
July 3, 2025
·
3 min read
Press Releases
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
June 9, 2025
·
3 min read
Press Releases
Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025
March 20, 2025
·
1 min read
Press Releases
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
June 4, 2025
·
10 min read
Press Releases
Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis
May 22, 2025
·
2 min read
Press Releases
Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis
June 18, 2025
·
2 min read
Press Releases
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
June 4, 2025
·
9 min read
Press Releases
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
May 6, 2025
·
2 min read
Press Releases
Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
May 20, 2025
·
3 min read
1 of 70,486
Next
